Towards Sustainable Pharma: Assessing Contribution To Sustainable Development Goals (Sdgs) Of Leading Companies

Abstract

The pharmaceutical industry, vital for global health, faces increasing scrutiny for its environmental impacts. This research evaluates the environmental sustainability initiatives of five prominent pharmaceutical companies: AstraZeneca plc, Pfizer Inc, Merck & Co., Inc, STADA Arzneimittel AG, and Ultragenyx Pharmaceutical Inc. Drawing from credible sources such as Corporate Knights, Barron's, and Sustainalytics, the study assesses these companies' environmental performance, initiatives, and achievements. Objectives include investigating their contribution to Sustainable Development Goals (SDGs), comparing sustainability efforts, and providing recommendations for industry enhancement. This study evaluates the environmental sustainability practices of five leading pharmaceutical companies, aiming to investigate their SDG contribution, compare sustainability efforts, and propose recommendations for industry enhancement. Selected based on top sustainability lists, data for the five companies were collected from various sources including annual reports and sustainability reports. Evaluation criteria encompassed alignment with global sustainability goals, effectiveness, transparency, innovation, and commitment to improvement. While AstraZeneca, Pfizer, Merck, STADA, and Ultragenyx exhibit commendable efforts, further collaboration and innovation are imperative for addressing industry challenges. By implementing suggested recommendations, pharmaceutical companies can advance sustainability efforts for a healthier planet. AstraZeneca plc, Pfizer Inc, Merck & Co., Inc, STADA Arzneimittel AG, and Ultragenyx Pharmaceutical Inc are evaluated for their contributions to SDGs, emphasizing their commitment to environmental sustainability